Photo by Getty Images
A new randomized study could reduce the morbidity and mortality associated with COVID-19 and streamline clinical research at Yale. The study will enroll 466 patients across five different Yale New Haven Hospital sites to identify a potential COVID-19 treatment.
Led by Alexandra Lansky, MD, a professor of medicine and director of the Yale Cardiovascular Research Group (YCRG), the COLSTAT clinical trial (Colchicine/Statin for the Prevention of COVID-19 Complications) will combine two widely available medications to reduce complications in infected patients. Both have been in use for decades and have no adverse effects in patients with COVID-19.